The adverse events during low-dose IL-2 treatment in SLE patients
| IL-2 (n=29) n (%) | Placebo (n=30) n (%) | |
| SAEs | 0 | 3 (10.0) |
| NPSLE | 0 | 1 (3.3) |
| Herpes zoster | 0 | 1 (3.3) |
| Pneumonia | 0 | 1 (3.3) |
| AEs | ||
| Infection | 2 (6.9) | 6 (20.0) |
| Upper respiratory infection | 2 (6.9) | 4 (13.3) |
| Severe infections | 0 | 2 (6.7) |
| Herpes zoster | 0 | 1 (3.3) |
| Pneumonia | 0 | 1 (3.3) |
| Injection site reactions | 9 (31.0) | 2 (6.7) |
| Fever | 4 (13.8) | 0 |
| Flu-like symptoms | 3 (10.3) | 0 |
.AE, adverse event; SAE, severe adverse events.